为了探讨精确放疗与替加氟和奈达铂同步放化疗在食管癌中的临床效果及应用价值,本研究收集我院食管鳞癌局部晚期的60例患者进行研究,精确放疗组予三维适形调强放射治疗,同步放化疗组在精确放疗基础上予替加氟和奈达铂联合化疗,并对两组的近期疗效、生存率和不良反应方面进行观察对比。研究发现,同步放化疗组总的有效率是83.3%,精确放疗组总的有效率为60.0%,同步放化疗组的近期疗效优于精确放疗组(p<0.05)。同步放疗组1、2年的生存率分别为88.7%、67.3%,精确放疗组分别为66.3%、40.6%,均低于同步放疗组(p<0.05),而且在生存期方面,同步放疗组要比精确放疗组时间长(p<0.05)。同步放化疗组患者的白细胞下降、消化道反应较精确化疗组表现较差(p<0.05),放射性食管炎和血小板下降两方面无统计学差异(p>0.05)。由此可以看出,替加氟和奈达铂同步放化疗治疗食管癌,可以增强患者的近期疗效,延长生存期,安全性和耐受性均可。 In order to explore the precise radiotherapy and tegafur and nedaplatin concurrent chemoradiotherapy in esophageal cancer clinical effect and application value, this study collected in our hospital esophageal squamous cell carcinoma of the local advanced 60 patients were studied, the precise radiotherapy group three-dimensional conformal IMRT, synchronous radiotherapy and chemotherapy group on the basis of accurate radiotherapy plus fluoride and nedaplatin combined with chemotherapy, and the two groups of short-term efficacy, survival and adverse reactions were observed and compared. The study found that the total effective rate of concurrent chemoradiotherapy was 83.3%, and the total effective rate was 60.0% in the precise radiotherapy group. The curative effect of the concurrent radiochemotherapy group was better than that of the precision radiotherapy group (p <0.05). The 1 and 2 year survival rates of concurrent radiotherapy group were 88.7% and 67.3%, respectively, which were 66.3% and 40.6% respectively in the radiotherapy group, which were lower than those in the concurrent radiotherapy group (p <0.05) Than the exact radiotherapy group for a long time (p <0.05). Patients with concurrent chemoradiotherapy had leukopenia, poor digestive tract response, poor response to chemotherapy (p <0.05), and no difference between esophagitis and thrombocytopenia (p> 0.05). It can be seen, tegafur and nedaplatin concurrent chemoradiotherapy for esophageal cancer, can enhance the patient’s immediate effect, prolong survival, safety and tolerability can be.